Journals / Turkish Journal of Gastroenterology / 2021 / Cilt: 32 - Sayı: 12

Pathologic Validation of Endoscopic Ablative Therapy for Gastric Epithelial Neoplasia: A Randomized Controlled Trial

Pages
1029–1037
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, endoscopic resection should be a first option for treatment of gastric epithelial neoplasia until the optimal method is established with further studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: The effectiveness of endoscopic ablative therapy such as monopolar coagulation (MC) or argon plasma coagulation (APC) have not been validated histologically.
📊
Key Findings & Data:Results: Sixty-eight patients were recruited, of whom 34 patients underwent APC and 34 patients underwent MC followed by ESD.
💡
Conclusion & Impact:Therefore, endoscopic resection should be a first option for treatment of gastric epithelial neoplasia until the optimal method is established with further studies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background: The effectiveness of endoscopic ablative therapy such as monopolar coagulation (MC) or argon plasma coagulation (APC) have not been validated histologically. The aim of this study was the histologic validation of endoscopic ablative therapy for gastric epithelial neoplasia. Methods: We designed a prospective randomized controlled trial involving patients with gastric low-grade dysplasia. Patients were randomly assigned to either the APC or the MC group. Endoscopic ablative therapy was followed by endoscopic submucosal dissection (ESD) for histologic evaluation. The main outcome was histologic completeness of endoscopic ablative therapy. Results: Sixty-eight patients were recruited, of whom 34 patients underwent APC and 34 patients underwent MC followed by ESD. The APC group showed significantly higher complete eradication rate compared to the MC group (55.9% vs. 11.8%, P < .001). APC was the only significant predictor of histologic complete eradication in multivariate analysis (OR: 7.66; 95% CI: 2.139-27.448). No adverse events related to the procedure occurred in either group. Conclusions: Although APC is a more effective treatment option than MC in the management of gastric epithelial neoplasia, the effectiveness of both methods was limited in eradicating gastric epithelial neoplasia completely. Therefore, endoscopic resection should be a first option for treatment of gastric epithelial neoplasia until the optimal method is established with further studies.

🔖

Cite This Article

HUH, C. W., KİM, J., KİM, B., KİM, J. S. (2021). Pathologic Validation of Endoscopic Ablative Therapy for Gastric Epithelial Neoplasia: A Randomized Controlled Trial. Turkish Journal of Gastroenterology, Cilt: 32 - Sayı: 12, 1029–1037. https://ajindex.com/articles/408843

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ahn JY, Jung HY, Choi KD, et al. Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications. Gastrointest Endosc. 2011
  2. 74(3):485-493. [CrossRef] 2. Vargo JJ. Clinical applications of the argon plasma coagulator. Gastrointest Endosc. 2004
  3. 59(1):81-88. [CrossRef] 3. Watson JP, Bennett MK, Griffin SM, Matthewson K. The tissue effect of argon plasma coagulation on esophageal and gastric mucosa. Gastrointest Endosc. 2000
  4. 52(3):342-345. [CrossRef] 4. Johanns W, Luis W, Janssen J, Kahl S, Greiner L. Argon plasma coagulation (APC) in gastroenterology: experimental and clinical experiences. Eur J Gastroenterol Hepatol. 1997
  5. 9(6):581-587. [CrossRef] 5. Sumiyama K, Kaise M, Kato M, et al. New-generation argon plasma coagulation in flexible endoscopy: ex vivo study and clinical experience. J Gastroenterol Hepatol. 2006
  6. 21(7):1122-1128. [CrossRef] 6. Grund KE, Zindel C, Farin G. Argon plasma coagulation through a flexible endoscope. Evaluation of a new therapeutic method after 1606 uses. Dtsch Med Wochenschr. 1997
  7. 122(14):432-438. [CrossRef] 7. Muguruma N, Okamoto K, Kimura T, et al. Endoscopic ablation therapy for gastrointestinal superficial neoplasia. Dig Endosc. 2012
  8. 24(3):139-149. [CrossRef] 8. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000
  9. 47(2):251-255. [CrossRef] 9. Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut. 2002
  10. 51(1):130-131. [CrossRef] 10. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012
  11. 44(1):74-94. [CrossRef] 11. Kim B, Kim BJ, Seo IK, Kim JG. Cost-effectiveness and short-term clinical outcomes of argon plasma coagulation compared with endoscopic submucosal dissection in the treatment of gastric lowgrade dysplasia. Med (Baltim). 2018
  12. 97(15):e0330. [CrossRef] 12. Oh S, Kim SG, Choi JM, et al. Ablation of residual gastric tumor by argon plasma coagulation after endoscopic resection. Surg Endosc. 2017
  13. 31(3):1093-1100. [CrossRef] 13. Lee DH, Bae WK, Kim JW, et al. The usefulness of argon plasma coagulation compared with endoscopic submucosal dissection to treat gastric adenoma. Korean J Ga